Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.

Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.

Author information

1
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Massachusetts General Hospital, 0 Emerson Place, Suite 118, Boston, MA 02114, USA. Electronic address: bdhunter@mgh.harvard.edu.
2
Massachusetts General Hospital, 0 Emerson Place, Suite 118, Boston, MA 02114, USA.
3
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

Abstract

Despite the myriad of available treatments, a substantial subset of patients with non-Hodgkin lymphoma are not able to achieve a prolonged disease-free interval with conventional chemotherapy or targeted agents. For these patients, hematopoietic stem cell transplantation remains an option for consolidative or curative treatment. Additionally, chimeric antigen receptor T-cell therapy has emerged for patients with relapsed/refractory B-cell lymphomas. Published studies vary widely in their selected approach to transplant and cellular therapies. This review summarizes available data related to allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy for the treatment of non-Hodgkin lymphomas.

KEYWORDS:

Allogeneic stem cell transplant; B-cell lymphoma; Chimeric antigen receptor T-cell therapy; Non-Hodgkin lymphoma; T-cell lymphoma

PMID:
31229163
DOI:
10.1016/j.hoc.2019.03.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center